medvisМедицинская визуализацияMedical Visualization1607-07632408-9516RDS-Media Ltd.10.24835/1607-0763-2020-1-119-132medvis-895Research ArticleНОВЫЕ ТЕХНОЛОГИИ ЛУЧЕВЫХ ИССЛЕДОВАНИЙNEW TECHNOLOGIES IN RADIOLOGYБиохимические основы визуализации при позитронной эмиссионной томографии в онкологии. Часть 2Biochemical basics of imaging in positron emission tomography in oncology. Part 2https://orcid.org/0000-0002-6345-9500ЛеонтьевА. В.LeontyevA. V.

канд. мед. наук, заведующий отделением радионуклидной диагностики 125284 Москва, 2 -й Боткинский пр., д. 3, Российская Федерация

Тел.: +7 (495) 9458718

Phone: +7 (495) 945-87-18

 

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

aleksleont@yandex.ruhttps://orcid.org/0000-0001-8378-4338РубцоваН. А.RubtsovaN. A.

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

rna17@yandex.ruhttps://orcid.org/0000-0002-8905-4202ХалимонА. И.KhalimonA. I.

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

markyhaws@gmail.comhttps://orcid.org/0000-0002-4864-0643ХамадееваГ. Ф.KhamadeevaG. F.

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

g.hamadeeva@yandex.ruhttps://orcid.org/0000-0002-3508-1782КулиевМ. Т.KulievM. T.

Resident of Oncology, Radiotherapy and Plastic Surgery Department of Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) based at the Nuclear Medicine Department 

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

kul502@yandex.ruhttps://orcid.org/0000-0002-1280-620XПыловаИ. В.PylovaI. V.

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

irinapylova@mail.ruhttps://orcid.org/0000-0002-7835-4939ЛазутинаТ. Н.LazutinaT. N.

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

t.n.lazutina@yandex.ruhttps://orcid.org/0000-0002-0792-6012КостинА. А.KostinA. A.

Doct. of Sci. (Med.), Professor, First Deputy of General director of “National Medical Research Center of Radiology” of the Ministry of Healthcare of Russia, Head of Urological, oncological and radiological department of Faculty of advanced training of medical workers of medical institute of The Peoples' Friendship University of Russia

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

andocrey@mail.ruhttps://orcid.org/0000-0001-8784-8415КапринА. Д.KaprinA. D.

Full Member of the Russian Academy of Sciences, Corresponding member of Russian Academy of Education, Doct. of Sci. (Med.), Professor, Honored Doctor of the Russian Federation, Chief urologist of the Russian Academy of Sciences, General Director of “National Medical Radiological Research Center” of the Ministry of Healthcare of Russia, Head of Department of urology and surgical  nephrology with a course of oncourology at the medical faculty of medical institute of The Peoples' Friendship University of Russia

3, 2nd Botkinsky pr., Moscow 125284, Russian Federation

kaprin@mail.ruМНИОИ имени П.А. Герцена – филиал ФГБУ “Национальный медицинский исследовательский центр радиологии” Минздрава РоссииРоссияP.A. Herzen Moscow Research Oncology Institute – branch of “National Medical Research Center of Radiology” of the Ministry of Healthcare of RussiaRussian Federation202002052020241Медицинская визуализация 2020№1119132Copyright © Леонтьев А.В., Рубцова Н.А., Халимон А.И., Хамадеева Г.Ф., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Костин А.А., Каприн А.Д., 20202020Леонтьев А.В., Рубцова Н.А., Халимон А.И., Хамадеева Г.Ф., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Костин А.А., Каприн А.Д.Leontyev A.V., Rubtsova N.A., Khalimon A.I., Khamadeeva G.F., Kuliev M.T., Pylova I.V., Lazutina T.N., Kostin A.A., Kaprin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medvis.rdsmedia.ru/jour/article/view/895ПЭТ/КТрадиофармпрепаратыРФПрецепторная визуализациялиганды к рецепторамRGD-пептидынейроэндокринные опухолиDOTA-пептидыDOTATATEDOTATOCDOTANOCлиганды к ПСМАлиганды к эстрогеновым рецепторамФЭСлиганды к рецепторам половых гормоновEGFRPET/CTradiopharmaceuticalsreceptor imagingreceptor ligandsRGD-peptidesNETDOTA-conjugated peptidesDOTATATEDOTATOCDOTANOCPSMA ligandsestrogen receptors imagingFESsex hormone imagingEGFRReferencesBrooks P.C., Strömblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinaseBrooks P.C., Strömblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 1996; 85 (5): 683–693. https://doi.org/10.1016/s0092-8674(00)81235-0MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 1996; 85 (5): 683–693. https://doi.org/10.1016/s0092-8674(00)81235-0Haubner R., Wester H.J., Reuning U., SenekowitschSchmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting. J. Nucl. Med. 1999; 40: 1061–1071.Haubner R., Wester H.J., Reuning U., SenekowitschSchmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting. J. Nucl. Med. 1999; 40: 1061–1071.Chen H., Niu G., Wu H., Chen X. Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3. Theranostics. 2016; 6 (1): 78–92. https://doi.org/10.7150/thno.13242Chen H., Niu G., Wu H., Chen X. Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3. Theranostics. 2016; 6 (1): 78–92. https://doi.org/10.7150/thno.13242Karen A., Kurdziel M.D., Lindenberg L., Choyke P.L. Oncologic angiogenesis imaging in the clinic – how and why. Imaging Med. 2011; 3 (4): 445–457.Karen A., Kurdziel M.D., Lindenberg L., Choyke P.L. Oncologic angiogenesis imaging in the clinic – how and why. Imaging Med. 2011; 3 (4): 445–457.Haubner R., Wester H.J., Reuning U., SenekowitschSchmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor targeting. J. Nucl. Med. 1999; 40 (6): 1061–1071.Haubner R., Wester H.J., Reuning U., SenekowitschSchmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor targeting. J. Nucl. Med. 1999; 40 (6): 1061–1071.Niu G., Chen X. RGD PET: From Lesion Detection to Therapy Response Monitoring. J. Nucl. Med. 2015; 57 (4): 501–502. https://doi.org/10.2967/jnumed.115.168278Niu G., Chen X. RGD PET: From Lesion Detection to Therapy Response Monitoring. J. Nucl. Med. 2015; 57 (4): 501–502. https://doi.org/10.2967/jnumed.115.168278Zhang H., Liu N., Gao S., Hu X., Zhao W., Tao R., Chen Z., Zheng J., Sun X., Xu L., Li W., Yu J., Yuan S. Can an 18F-AlF-NOTA-PRGD2 PET/CT scan predict the treatment sensitivity of concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma? J. Nucl. Med. 2016; 57: 524–529. https://doi.org/10.2967/jnumed.115.165514Zhang H., Liu N., Gao S., Hu X., Zhao W., Tao R., Chen Z., Zheng J., Sun X., Xu L., Li W., Yu J., Yuan S. Can an 18F-AlF-NOTA-PRGD2 PET/CT scan predict the treatment sensitivity of concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma? J. Nucl. Med. 2016; 57: 524–529. https://doi.org/10.2967/jnumed.115.165514Cescato R., Schulz S., Waser B., Eltschinger V., Rivier J.E., Wester H.J., Culler M., Ginj M., Liu Q., Schonbrunn A., Reubi J.C. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J. Nucl. Med. 2006; 47 (3): 502–511. https://doi.org/10.1111/bph.12551Cescato R., Schulz S., Waser B., Eltschinger V., Rivier J.E., Wester H.J., Culler M., Ginj M., Liu Q., Schonbrunn A., Reubi J.C. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J. Nucl. Med. 2006; 47 (3): 502–511. https://doi.org/10.1111/bph.12551Sollini M., Erba P.A., Fraternali A. PET and PET/CT with 68Gallium-labeled somatostatin analogues in non GEPNETs tumors. Sci. Wld J. 2014; 2014: Article ID 194123. https://doi.org/10.1155/2014/194123Sollini M., Erba P.A., Fraternali A. PET and PET/CT with 68Gallium-labeled somatostatin analogues in non GEPNETs tumors. Sci. Wld J. 2014; 2014: Article ID 194123. https://doi.org/10.1155/2014/194123Hofland L.J., Lamberts S.W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 2003; 24: 28–47. https://doi.org/10.1210/er.2000-0001Hofland L.J., Lamberts S.W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 2003; 24: 28–47. https://doi.org/10.1210/er.2000-0001Virgolini I., Ambrosini V., Bomanji J.B., Baum R.P., Fanti S., Gabriel M., Papathanasiou N.D., Pepe G., Oyen W., De Cristoforo C., Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging. 2010; 37: 2004–2010. https://doi.org/10.1007/s00259-010-1512-3Virgolini I., Ambrosini V., Bomanji J.B., Baum R.P., Fanti S., Gabriel M., Papathanasiou N.D., Pepe G., Oyen W., De Cristoforo C., Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging. 2010; 37: 2004–2010. https://doi.org/10.1007/s00259-010-1512-3Geijer H., Breimer L.H. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J. Nucl. Med. Mol. Imaging. 2013; 40 (11): 1770–1780. https://doi.org/10.1007/s00259-013-2482-zGeijer H., Breimer L.H. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J. Nucl. Med. Mol. Imaging. 2013; 40 (11): 1770–1780. https://doi.org/10.1007/s00259-013-2482-zFani M., Nicolas G.P., Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. J. Nucl. Med. 2017; 58 (Suppl. 2): 61S–66S. https://doi.org/10.2967/jnumed.116.186783Fani M., Nicolas G.P., Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. J. Nucl. Med. 2017; 58 (Suppl. 2): 61S–66S. https://doi.org/10.2967/jnumed.116.186783Chan D.L.H., Pavlakis N., Schembri G.P., Bernard E.J., Hsiao E., Hayes A., Barnes T., Diakos C., Khasraw M., Samra J., Eslick E., Roach P.J., Clarke S.J., Bailey D.L. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017; 7 (5): 1149–1158. https://doi.org/10.7150/thno.18068Chan D.L.H., Pavlakis N., Schembri G.P., Bernard E.J., Hsiao E., Hayes A., Barnes T., Diakos C., Khasraw M., Samra J., Eslick E., Roach P.J., Clarke S.J., Bailey D.L. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017; 7 (5): 1149–1158. https://doi.org/10.7150/thno.18068Hindié E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics. 2017; 7 (5): 1159–1163. https://doi.org/10.7150/thno.19588Hindié E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics. 2017; 7 (5): 1159–1163. https://doi.org/10.7150/thno.19588Fani M., Nicolas G.P., Wild D. Somatostatin receptor antagonists for imaging and therapy. J. Nucl. Med. 2017; 58: 61S–66S. https://doi.org/10.2967/jnumed.116.186783Fani M., Nicolas G.P., Wild D. Somatostatin receptor antagonists for imaging and therapy. J. Nucl. Med. 2017; 58: 61S–66S. https://doi.org/10.2967/jnumed.116.186783Fani M., Peitl P.K., Velikyan I. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals. 2017; 10 (1): 30. https://doi.org/10.3390/ph10010030Fani M., Peitl P.K., Velikyan I. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals. 2017; 10 (1): 30. https://doi.org/10.3390/ph10010030Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J., Mäcke H.R., Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proceedings of the National Academy of Sciences. 2006; 103 (44): 16436–16441. https://doi.org/10.1073/pnas.0607761103Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J., Mäcke H.R., Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proceedings of the National Academy of Sciences. 2006; 103 (44): 16436–16441. https://doi.org/10.1073/pnas.0607761103Lenzo N., Cardaci J., Meyrick D., Henderson A., Crouch J., Yeo S., Turner H. Lu-177 OPS-201 (satareotide) Trial for Metastatic Neuroendocrine Tumour. Доступно по: http://theranostics.com.au/wp-content/uploads/2016/05/Lu-177-OPS-201-Satareotide-Trial-for-Metastatic-Neuroendocrine-Tumours.pdf. Ссылка активна на 01.07.2019г.Lenzo N., Cardaci J., Meyrick D., Henderson A., Crouch J., Yeo S., Turner H. Lu-177 OPS-201 (satareotide) Trial for Metastatic Neuroendocrine Tumour. Доступно по: http://theranostics.com.au/wp-content/uploads/2016/05/Lu-177-OPS-201-Satareotide-Trial-for-Metastatic-Neuroendocrine-Tumours.pdf. Ссылка активна на 01.07.2019г.Rylova S.N., Stoykow C., Del Pozzo L., Abiraj K., Tamma M.L., Kiefer Y., Fani M., Maecke H.R. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. PLoS One. 2018; 13 (4): e0195802. https://doi.org/10.1371/journal.pone.0195802Rylova S.N., Stoykow C., Del Pozzo L., Abiraj K., Tamma M.L., Kiefer Y., Fani M., Maecke H.R. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. PLoS One. 2018; 13 (4): e0195802. https://doi.org/10.1371/journal.pone.0195802Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J.R. Mäcke H.R, Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. USA. 2006; 3 (44): 16436–16441. https://doi.org/10.1073/pnas.0607761103Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J.R. Mäcke H.R, Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. USA. 2006; 3 (44): 16436–16441. https://doi.org/10.1073/pnas.0607761103Nicolas G.P., Schreiter N., Kaul F., Uiters J., Bouterfa H., Kaufmann J., Wild D. Sensitivity comparison of 68GaOPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospec tive phase II imaging study. J. Nuclear Med. 2017; 59 (6): 915–921. https://doi.org/10.2967/jnumed.117.199760Nicolas G.P., Schreiter N., Kaul F., Uiters J., Bouterfa H., Kaufmann J., Wild D. Sensitivity comparison of 68GaOPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospec tive phase II imaging study. J. Nuclear Med. 2017; 59 (6): 915–921. https://doi.org/10.2967/jnumed.117.199760Kunz P.L. Carcinoid and neuroendocrine tumors: building on success. J. Clin. Oncol. 2015; 33: 1855–1863. https://doi.org/10.1200/JCO.2014.60.2532Kunz P.L. Carcinoid and neuroendocrine tumors: building on success. J. Clin. Oncol. 2015; 33: 1855–1863. https://doi.org/10.1200/JCO.2014.60.2532Endocrinology: National guidelines. Brief Edition / Eds I.I.Dedova, G.A. Melnichenko. M.: GEOTAR-Media, 2013. 752 p. (In Russian)Эндокринология: Национальное руководство. Краткое издание / Под ред. И.И. Дедова, Г.А. Мельниченко. М.: ГЭОТАР-Медиа, 2013. 752 с.Bozkurt M.F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., Ambrosini V., Kjaer A., Delgado-Bolton R., Kunikowska J., Oyen W.J.G., Chiti A., Giammarile F., Sundin A., Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTAconjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1588–1601. https://doi.org/10.1007/s00259-017-3728-yBozkurt M.F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., Ambrosini V., Kjaer A., Delgado-Bolton R., Kunikowska J., Oyen W.J.G., Chiti A., Giammarile F., Sundin A., Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTAconjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1588–1601. https://doi.org/10.1007/s00259-017-3728-yKhayum M.A., Doorduin J. Glaudemans A.W.J.M., Dierckx R.A.J.O. , E.F.J., de Vries R.A.J.O. PET and SPECT of Neurobiological Systems. Chapter 14. Berlin; Heidelberg: Springer-Verlag, 2014.Khayum M.A., Doorduin J. Glaudemans A.W.J.M., Dierckx R.A.J.O. , E.F.J., de Vries R.A.J.O. PET and SPECT of Neurobiological Systems. Chapter 14. Berlin; Heidelberg: Springer-Verlag, 2014.Liu C., Gong C., Liu S., Zhang Y., Zhang Y., Xu X., Yuan H., Wang B., Yang Z. 18F-FES PET/CT influences the staging and management of newly diagnosed Oestrogen Receptor positive Breast Cancer Patients: A Retrospective Comparative Study with 18F-FDG PET/CT. J. Nucl. Med. 2019; 60 (1): 596.Liu C., Gong C., Liu S., Zhang Y., Zhang Y., Xu X., Yuan H., Wang B., Yang Z. 18F-FES PET/CT influences the staging and management of newly diagnosed Oestrogen Receptor positive Breast Cancer Patients: A Retrospective Comparative Study with 18F-FDG PET/CT. J. Nucl. Med. 2019; 60 (1): 596.Sun Y., Yang Z., Zhang Y., Xue J., Wang M., Shi W., Zhu B., Hu S., Yao Z., Pan H., Zhang Y. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. PLoS ONE. 2015; 10 (1): e0116341. https://doi.org/10.1371/journal.pone.0116341Sun Y., Yang Z., Zhang Y., Xue J., Wang M., Shi W., Zhu B., Hu S., Yao Z., Pan H., Zhang Y. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. PLoS ONE. 2015; 10 (1): e0116341. https://doi.org/10.1371/journal.pone.0116341Nienhuis H.H., van Kruchten M., Elias S.G., Glaudemans A.W.J.M., de Vries E.F.J., Bongaerts A.H.H., Schröder C.P., de Vries E.G.E., Hospers G.A.P. 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. J. Nucl. Med. 2018; 59 (8): 1212–1218. https://doi.org/10.2967/jnumed.117.198846Nienhuis H.H., van Kruchten M., Elias S.G., Glaudemans A.W.J.M., de Vries E.F.J., Bongaerts A.H.H., Schröder C.P., de Vries E.G.E., Hospers G.A.P. 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. J. Nucl. Med. 2018; 59 (8): 1212–1218. https://doi.org/10.2967/jnumed.117.198846Gong C., Yang Z., Sun Y., Zhang J., Zheng C., Wang L., Zhang Y., Xue J., Yao Z., Pan H., Wang B., Zhang Y. A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Scientific Reports. 2017; 7: 6584. https://doi.org/10.1038/s41598-017-06903-8Gong C., Yang Z., Sun Y., Zhang J., Zheng C., Wang L., Zhang Y., Xue J., Yao Z., Pan H., Wang B., Zhang Y. A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Scientific Reports. 2017; 7: 6584. https://doi.org/10.1038/s41598-017-06903-8Mertan F.V., Lindenberg L., Choyke P.L., Turkbey B. PET imaging of recurrent and metastatic prostate cancer with novel tracers. Future Oncol. 2016; 12 (21): 2463–2477. https://doi.org/10.2217/fon-2016-0270Mertan F.V., Lindenberg L., Choyke P.L., Turkbey B. PET imaging of recurrent and metastatic prostate cancer with novel tracers. Future Oncol. 2016; 12 (21): 2463–2477. https://doi.org/10.2217/fon-2016-0270Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; C (7): 27–935.Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; C (7): 27–935.Afshar-Oromieh A., Babich J.W., Giesel C.K.F.L., Eisenhut M., Kopka K., Haberkorn U. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. J Nucl Med. 2016;57:79S–89S. https://doi.org/10.2967/jnumed.115.170720Afshar-Oromieh A., Babich J.W., Giesel C.K.F.L., Eisenhut M., Kopka K., Haberkorn U. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. J Nucl Med. 2016;57:79S–89S. https://doi.org/10.2967/jnumed.115.170720Giesel F.L., Kesch C., Yun M., Cardinale J., Haberkorn U., Kopka K., Kratochwil C., Hadaschik B.A. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin. Genitourin Cancer. 2017; 15 (3): 497–499. https://doi.org/10.1016/j.clgc.2016.12.029Giesel F.L., Kesch C., Yun M., Cardinale J., Haberkorn U., Kopka K., Kratochwil C., Hadaschik B.A. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin. Genitourin Cancer. 2017; 15 (3): 497–499. https://doi.org/10.1016/j.clgc.2016.12.029Leontyev A.V., Rubtsova N.A., Khalimon A.I., Kuliev M.T., Pylova I.V., Lazutina T.N., Khamadeeva G.F., Alekseev B.Ya., Kostin A.A., Kaprin A.D. Application of radiolabeled ligands to the prostate-specific membrane antigen for determine localization of biochemical recurrence of prostate cancer by PET/CT (literature review). Medical Visualization. 2018; 22 (3): 81–97. https://doi.org/10.24835/1607-0763-2018-3-81-97 (In Russian)Леонтьев А.В., Рубцова Н.А., Халимон А.И., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Хамадеева Г.Ф., Алексеев Б.Я., Костин А.А., Каприн А.Д. Применение радиомеченых лигандов к простатспецифическому мембранному антигену для определения локализации био химического рецидива рака предстательной железы методом ПЭТ/КТ (обзор литературы). Медицинская визуализация. 2018; 22 (3): 81–97. https://doi.org/10.24835/1607-0763-2018-3-81-97.Afshar-Oromieh A., Holland-Letz T., Giesel F.L., Kratochwil C., Mier W., Haufe S., Debus N., Eder M., Eisenhut M., Schäfer M., Neels O., Hohenfellner M., Kopka K., Kauczor H.U., Debus J., Haberkorn U. Diagnostic performance of (68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (8): 1258–1268. https://doi.org/10.1007/s00259-017-3711-7Afshar-Oromieh A., Holland-Letz T., Giesel F.L., Kratochwil C., Mier W., Haufe S., Debus N., Eder M., Eisenhut M., Schäfer M., Neels O., Hohenfellner M., Kopka K., Kauczor H.U., Debus J., Haberkorn U. Diagnostic performance of (68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (8): 1258–1268. https://doi.org/10.1007/s00259-017-3711-7Schwenck J., Rempp H., Reischl G., Kruck S., Stenzl A., Nikolaou K., Pfannenberg C., la Fougère C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (1): 92–101. https://doi.org/10.1007/s00259-016-3490-6Schwenck J., Rempp H., Reischl G., Kruck S., Stenzl A., Nikolaou K., Pfannenberg C., la Fougère C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (1): 92–101. https://doi.org/10.1007/s00259-016-3490-6Roach P.J., Francis R., Emmett L., Hsiao E., Kneebone A., Hruby G., Eade T., Nguyen Q.A., Thompson B.D., Cusick T., McCarthy M., Tang C., Ho B., Stricker P.D., Scott A.M. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study. J. Nucl. Med. 2018; 59 (1): 82–88. https://doi.org/10.2967/jnumed.117.197160Roach P.J., Francis R., Emmett L., Hsiao E., Kneebone A., Hruby G., Eade T., Nguyen Q.A., Thompson B.D., Cusick T., McCarthy M., Tang C., Ho B., Stricker P.D., Scott A.M. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study. J. Nucl. Med. 2018; 59 (1): 82–88. https://doi.org/10.2967/jnumed.117.197160Albisinni S., Artigas C., Aoun F., Biaou I., Grosman J., Gil T., Hawaux E., Limani K., Otte F.X., Peltier A., Sideris S., Sirtaine N., Flamen P., van Velthoven R. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: Preliminary analysis of a multidisciplinary approach. BJU Int. 2017; 120 (2): 197–203. https://doi.org/10.1111/bju.13739Albisinni S., Artigas C., Aoun F., Biaou I., Grosman J., Gil T., Hawaux E., Limani K., Otte F.X., Peltier A., Sideris S., Sirtaine N., Flamen P., van Velthoven R. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: Preliminary analysis of a multidisciplinary approach. BJU Int. 2017; 120 (2): 197–203. https://doi.org/10.1111/bju.13739Veliev E.I., Tomilov A.A., Bogdanov A.B. Salvage lymph node dissection in patients with oligometastatic recurrence of prostate cancer confirmed by PET-CT. Cancer Urology. 2018; 14 (4): 79–86. https://doi.org/10.17650/1726-9776-2018-14-4-79-86 (In Russian)Велиев Е.И., Томилов А.А., Богданов А.Б. Спасительная лимфаденэктомия у пациентов с подтвержденным ПЭТ/КТ олигометастатическим рецидивом рака предстательной железы. Онкоурология. 2018; 14 (4): 79–86. https://doi.org/10.17650/1726-9776-2018-14-4-79-86Kabasakal L., Demirci E., Ocak M. et al. Evaluation of PSMA PET/CT imaging using a 68Ga- HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl. Med. Commun. 2015; C-36 (6): 582–587.Kabasakal L., Demirci E., Ocak M. et al. Evaluation of PSMA PET/CT imaging using a 68Ga- HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl. Med. Commun. 2015; C-36 (6): 582–587.Giesel F.L., Knorr K., Spohn F. et al. Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 2018; 60 (3): 362–368. https://doi.org/10.2967/jnumed.118.212233Giesel F.L., Knorr K., Spohn F. et al. Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 2018; 60 (3): 362–368. https://doi.org/10.2967/jnumed.118.212233Sakaeva D.D., Gordiev M.G. Epidermal growth factor receptor as target of molecular-targeted therapy in patients with primary non-small cell lung cancer. Malignant Tumours.2016; 3: 54–59. https://doi.org/10.18027/2224-5057-2016-3-54-59 (In Russian)Сакаева Д.Д., Гордиев М. Г. Рецептор эпидермального фактора роста как мишень молекулярно-направленной терапии у непредлеченых пациентов с немелкоклеточным раком легкого. Злокачественные опухоли. 2016; 3 (19). https://doi.org/10.18027/2224-5057-2016-3-54-59Gorbunova V.A., Artamonova E.V., Breder V.V., Laktionov K.K., Moiseenko F.V., Reutova E.V. et al. Practical guidelines for the treatment of non-small cell lung cancer. Malignant tumors: Practical guidelines for RUSSCO; 3s2, 2017 (Volume 7). p. 28–42. (In Russian)Горбунова В.А., Артамонова Е.В., Бредер В.В., Лактионов К.К., Моисеенко Ф.В., Реутова Е.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли: Практические рекомендации RUSSCO; 3s2, 2017 (т. 7): с. 28–42.Sun X., Xiao Z.,Chen G. et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl. Med. 2018: 7: 10 (431). https://doi.org/10.1126/scitranslmed.aan8840Sun X., Xiao Z.,Chen G. et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl. Med. 2018: 7: 10 (431). https://doi.org/10.1126/scitranslmed.aan8840Sun X., Xiao Z.,Chen G. et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl. Med. 2018: 7: 10 (431). https://doi.org/10.1126/scitranslmed.aan8840

The authors declare that there are no conflicts of interest present.